Search | Clinical Trials Finder

Conditions: Acromegaly
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • New York, New York

Conditions: Chronic Lymphocytic Leukemia
Interventions: CpG 7909; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Iowa City, Iowa • Rochester, Minnesota

Conditions: Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors
Interventions: Lanreotide, Y-90 microspheres; Drug · Device
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Denver, Colorado • Kansas City, Missouri • Nashville, Tennessee

Conditions: Congestive Heart Failure
Interventions: Nesiritide, Placebo, Saline; Drug
Lead sponsor: Horng Chen; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Peanut Allergies
Interventions: MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle); Drug
Lead sponsor: Mabylon AG; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more

Conditions: Atopic Dermatitis
Interventions: Barzolvolimab, Matching placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 12
States / cities: Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more

Conditions: Healthy Adult Subjects
Interventions: Pegilodecakin; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Irvine, California • San Diego, California • Walnut Creek, California + 6 more

Conditions: Graves' Disease, Graves Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: Orange, California • Pasadena, California • Fleming Island, Florida + 17 more

Conditions: ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran Sodium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 141
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more

Conditions: Dermatitis, Atopic
Interventions: Spesolimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more

Conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Interventions: Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol (CZP), Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 101
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more

Conditions: Moderate to Severe Genital Psoriasis
Interventions: Tildrakizumab 100 mg, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Anaheim, California • Encinitas, California • Encino, California + 30 more

Conditions: Zika Virus
Interventions: TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Neutropenia (Low White Blood Cell Count)
Interventions: Filgrastim Hospira (US), U.S.-approved Neupogen®; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Lyme Disease
Interventions: 2217LS, 0.9% Sodium Chloride (NaCl); Biological · Other
Lead sponsor: MassBiologics; Other
Eligibility: 19 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Asthma
Interventions: Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 23
States / cities: Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more

Conditions: Migraine
Interventions: Erenumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 37 more

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions: gilteritinib, azacitidine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 7 more

Conditions: Autism Spectrum Disorder, Atopy
Interventions: Omalizumab Injection [Xolair]; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 30 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 36 more

Search by objective public record fields.

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

A Study of Barzolvolimab in Patients With Atopic Dermatitis

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)

First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Xolair Interventional Study in ASD Patients With Comorbid Atopy

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program